A major study aiming to improve outcomes from higher-risk operations has ruled out a fluid therapy approach during surgery.
10h
Breast cancer liquid biopsy industry is projected to witness a CAGR of 22.6% during the period 2024-2032. This growth can be attributed to the rising awareness for early diagnosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback